NCT06735105 Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer
| NCT ID | NCT06735105 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yunnan Cancer Hospital |
| Condition | Gastric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 129 participants |
| Start Date | 2023-12-23 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 129 participants in total. It began in 2023-12-23 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Accurate staging is critical for effective gastric cancer treatment planning. Conventional DWI (C-DWI) has limitations in image quality due to magnetic field inhomogeneity, which hampers precise T staging. This study aims to compare the image quality and T staging accuracy of C-DWI, TSE-DWI, and ZOOMit-DWI (Z-DWI) sequences in MRI examinations of gastric cancer patients. A prospective study plan to enroll 72 gastric cancer patients undergoing preoperative MRI with C-DWI, TSE-DWI, and Z-DWI sequences using a 3.0 T scanner. Quantitative metrics (ADC, SNR, CNR) and image quality were evaluated. T staging accuracy was assessed by comparing MRI results with postoperative pathological staging using ROC analysis.
Eligibility Criteria
Inclusion Criteria: 1. The patient was diagnosed with gastric cancer by pathological biopsy 2. No biopsy was taken within 1 week before MR Examination to rule out the effect of bleeding on the image 3. No contraindications for MRI examination; And exclude serious heart, liver, kidney, cerebrovascular diseases. Exclusion Criteria: 1. The image quality cannot meet the diagnostic criteria; 2. Patients could not tolerate MRI examination, resulting in incomplete MR-related sequence image data.
Contact & Investigator
Lianhua Ye
STUDY DIRECTOR
Ethics Committee of Yunnan Provincial Cancer Hospital
Frequently Asked Questions
Who can join the NCT06735105 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06735105 currently recruiting?
Yes, NCT06735105 is actively recruiting participants. Contact the research team at lyl2241@163.com for enrollment information.
Where is the NCT06735105 trial being conducted?
This trial is being conducted at Kunming, China.
Who is sponsoring the NCT06735105 clinical trial?
NCT06735105 is sponsored by Yunnan Cancer Hospital. The principal investigator is Lianhua Ye at Ethics Committee of Yunnan Provincial Cancer Hospital. The trial plans to enroll 129 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.